Kyle LaHucik

Rhythm Phar­ma­ceu­ti­cals re­ceived FDA ap­proval to mar­ket its ge­net­ic obe­si­ty drug Im­civree for chil­dren as young as 2 years old. Fri­day’s ac­tion will let the

Sofinno­va In­vest­ments, one of the longest-stand­ing biotech in­vest­ment firms, has pen­ciled in plans for a new $550 mil­lion fund, End­points News has learned. The Men­lo

Syn­cro­mune, a biotech start­up work­ing on com­bi­na­tion im­munother­a­pies, has put to­geth­er a $100 mil­lion Se­ries A, the com­pa­ny told End­points News. The round was led

Ring Ther­a­peu­tics, a start­up look­ing to ad­vance a new type of virus to de­liv­er gene ther­a­pies, has let go “just un­der 50%” of its work­force

BioAge Labs, which be­gan near­ly a decade ago as an an­ti-ag­ing biotech and then turned to obe­si­ty this year, is go­ing back to its roots

Shi­no­bi Ther­a­peu­tics, an off-the-shelf cell ther­a­py de­vel­op­er, told End­points News it has hired its first chief sci­en­tif­ic and med­ical of­fi­cers as it al­so nabs two